WEST

Analyst Note: Westrock Coffee Company, LLC (WEST)

Date: 2026-06-20 Current Price: $9.03

1. Structural Readiness

• State: Context-Only (No technical structure defined in source data)
• Conservative Entry: —
• Breakout Level: —
• Current Price: $9.03
• Extension: —
• ATR Context: 6.3% (Very High). This indicates elevated volatility, which typically requires wider stops or smaller position sizing if a structure were to form.

2. Thesis Layer

• Thesis Classification: Tactical, Setup-Led.
• Macro Thesis: None. There is no named secular thesis (e.g., "Cold Brew Dominance" or "Private Label Shift") explicitly attached to this specific trade setup as of 2026-06-20.
• Judgment Criteria: The investment case must be judged strictly on the quality of the business fundamentals (EBITDA trajectory, Conway facility commercialization) and the technical setup quality once defined. Do not invent a macro narrative to justify the position. The name is a tactical play on operational turnaround and capital efficiency, not a structural secular growth story at this specific date.

3. The Business

Westrock Coffee Company, LLC is an integrated beverage solutions platform serving major brands across packaged coffee, tea, ready-to-drink (RTD) coffee, energy, and functional beverage categories. The company operates a "formulate, fill, and ship" model across multiple formats (cans, glass, bottles, single-serve) from an integrated footprint.

Key Operational & Financial Data (as of 2026-06-20):

• Revenue Growth: Consolidated net sales increased 44% year-over-year to approximately $309 million (Q1 2026).
• EBITDA Outlook: Management reaffirmed a 2026 consolidated adjusted EBITDA outlook of $90 million to $100 million.
• Capital Intensity Shift: The company reports a structural shift in capital profile. Capital intensity is expected to decline from $160 million (2024) to $89 million (2025) to an expected $30 million in 2026, driven by the full commercialization of the Conway, Arkansas facility.
• Conway Facility Status: Construction began in late 2022 and became fully operational in 2025. Management expects volume from this facility to begin arriving in late 2026, with full replacement targeted by the end of 2027.
• Product Mix: The "Liquid Extracts" segment (iced coffees, cold brew, RTD mixes) is the highest growth category. The company is expanding beyond single SKUs to full-spectrum partnerships (tea, lemonade, energy drinks, high-protein drinks, seltzers).
• Customer Concentration: The top five customers accounted for approximately 35% of net sales in fiscal 2025.
• Financial Health:
• Outstanding borrowings under the Revolving Credit Facility: $165.0 million (weighted average interest rate 7.7%).
• Credit Agreement Maturity: August 29, 2027.
• Liquidity: Management believes projected cash flows and available borrowings will be sufficient to fund operations and maintain covenant compliance for at least the next twelve months.
• Historical Losses: The company incurred net losses of $90.4 million (2025), $80.3 million (2024), and $34.6 million (2023).

4. Archetype and Conviction

• Archetype: Margin Inflector / Deep Value Recovery.
• The company is transitioning from a high-capital intensity, loss-making growth phase (2023-2025) to a cash-flow positive, low-capital intensity operational phase (2026+).
• The "Margin Inflector" thesis is supported by the projected drop in capital intensity to $30 million in 2026 and the reaffirmed EBITDA guidance of $90–$100 million.
• The "Deep Value Recovery" aspect is evident in the shift from cumulative losses to a path toward profitability, driven by the Conway facility reaching commercial scale.
• Conviction Stack:
• Thesis Strength: Moderate. The business model is sound (integrated platform), but the lack of a named secular thesis limits the "story" premium.
• Evidence Quality: High. Management has provided specific, quantitative guidance on EBITDA ($90–$100M), capital intensity ($30M), and facility timelines.
• Structural Quality: Improving. The reduction in capex and the move toward positive operating cash flows (anticipated late 2026) represent a fundamental structural improvement.
• Setup Readiness: Low/Unknown. The technical setup is undefined. The "Context-Only" status means the trade is not technically actionable based on the provided data.
• Rerating Potential: High, contingent on the successful commercialization of the Conway facility and the realization of the EBITDA guidance.
• Volatility Context: The current ATR of 6.3% (Very High) suggests significant price swings. This aligns with a company in a critical transition phase (commercialization of a new facility, path to profitability).

5. Invalidations, Strengtheners, and Gaps

• Invalidation Triggers:
• Failure to generate positive operating cash flows from the Conway facility by the anticipated timeframe (late 2026).
• Inability to maintain covenant compliance on the Credit Agreement (maturing Aug 2027).
• A significant drop in EBITDA below the $90 million guidance range.
• Strengtheners:
• Confirmation of volume arrival from Conway in late 2026 as guided.
• Successful commercialization of new product categories (energy, high-protein, seltzers) as mentioned in the transcript.
• Reduction in net losses to zero or positive net income in the next reporting cycle.
• Gaps in Evidence:
• Customer Retention: While top 5 customers are 35%, there is no data on churn or new customer acquisition rates beyond the "progress" mentioned.
• Debt Service Coverage: While management claims sufficiency for 12 months, specific debt service coverage ratios are not provided in the evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Reaffirmed 2026 EBITDA guidance of $90M-$100M; projected capital intensity drop to $30M in 2026; Conway facility fully operational with volume expected late 2026. Key risks: Failure to commercialize Conway facility on schedule; high interest rate environment impacting $165M debt load; continued net losses despite EBITDA guidance; lack of defined technical entry structure. Sizing hint: Position size must be reduced due to very high ATR (6.3%) and undefined technical setup; treat as a binary outcome on facility commercialization. Expected path: Management expects capital intensity to normalize and EBITDA to hit guidance; if Conway scales, the company should transition to positive operating cash flow by late 2026. Expected horizon: 12 to 18 months (through late 2026 commercialization milestones). Failure mode to watch: A breach of credit covenants or a public downgrade of the 2026 EBITDA guidance due to Conway delays.